The cannabis industry in Canada is suffering from product recalls due to harmful mold and mislabeling issues.
Beginning in September 2023, thousands of cannabis products have been recalled in Canada from various licensed producers due to numerous issues such as mislabeling on packages and harmful mold (1). Port Elgin, Ontario is the area suffering from the most recent recall. The licensed producer Coulson Cannabis had to issue a recall this month due to microbial contamination.
Canada’s government has a portal for recalls and safety alerts where notices can be posted and one was published that mentioned “the affected products might contain mold that could pose a risk of gastrointestinal symptoms and infections for consumers with compromised immune systems,” (1).
It is estimated that 660 units of product that were recalled were sold via authorized retailers located in Ontario from September 14 – October 3, 2023.
Health Canada has mentioned that Coulson Cannabis did receive one complaint specific to the recalled batch. Luckily, no adverse health reactions have been reported.
One of the most common reasons of cannabis recalls has been due to labeling errors. In the beginning of October, Emblem Cannabis Corp., which is a division of Aleafia Health based in Toronto, needed to recall a batch of cannabis extract that was sold through authorized retailers (1). The recall occurred after a decision from the Ontario Superior Court of Justice had agreed on approving a plan that allowed Red White & Bloom, a multistate operator (MSO), to acquire Aleafia. This deal was approved in August 2023.
Emblem Cannabis Corp. mentioned that the products that were affected had been sold between May 12 – October 3, 2023. The recall was caused from mislabeling and the products contained the incorrect cannabinoid values. An example of when this can occur is when the amount on the label, such as for the cannabinoid cannabidiol (CBD), is lower than the true value in the product.
Whenever there is a cannabis product recall, Health Canada recommends consumers reaching out to their retailers where the products were obtained.
Reference
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.